Information Provided By: 
Fly News Breaks for March 13, 2018
IOVA
Mar 13, 2018 | 05:30 EDT
Iovance Biotherapeutics last night provided an update on four ongoing clinical programs and its regulatory strategy for the melanoma program, Jefferies analyst Biren Amin writes in a post-earnings research note. Iovance continues to have an ongoing FDA dialogue and it is possible the company may be allowed to expand the current trial, the analyst adds. He sees the company's updates from Phase II melanoma, head and neck, and/or cervical studies in 2018 providing further share upside. Amin keeps a Buy rating on Iovance with a $31 price target.
News For IOVA From the Last 2 Days
There are no results for your query IOVA
